We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




ctDNA-Based MRD Test to Detect As Few As One Mutant Molecule in a Million DNA Molecules

By LabMedica International staff writers
Posted on 02 Dec 2022

Circulating tumor DNA (ctDNA) detection is a non-invasive method to assess tumor burden with a blood sample. More...

Recent data also correlate ctDNA levels in post-surgical cancer patients with recurrence-free survival (RFS) and risk of recurrence. Now, a best-in-class personalized cancer diagnostic test that is currently under development and planned for 2023 commercialization can detect as few as one mutant molecule in a million DNA molecules, positioning it as the most sensitive ctDNA-based MRD test for use in solid tumors.

Haystack Oncology (Baltimore, MD, USA) plans to expand accessibility to its groundbreaking ctDNA-based MRD testing platform, Haystack Duo, a low-error rate, next-generation chemistry that enables ultrasensitive and personalized MRD testing. Liquid biopsy approach delivers unparalleled sensitivity and specificity for detection of low-frequency mutant molecules to see what others can't. Haystack is pioneering research in liquid biopsy technologies to detect with high sensitivity and specificity the presence of any traces of MRD – small numbers of residual tumor DNA molecules left in the body following initial treatment. These ctDNA molecules are a marker of the presence of cancer and indicate that the disease will recur. Haystack's testing is designed to help inform clinical interventions by creating personalized diagnostic panels to customize optimal treatment plans for each patient, independent of a tumor's origin.

Haystack's tumor-informed liquid-biopsy-based test begins with tissue-based whole-exome sequencing to identify patient-specific tumor mutations. A personalized MRD test is then developed to detect ctDNA from residual, recurrent or resistant disease. A version of Haystack's technology was utilized in the landmark DYNAMIC clinical study of stage II colon cancer patients post-surgery. Results from the study reported earlier this year demonstrated that applying Haystack's ctDNA-guided approach to the treatment of stage II colon cancer significantly reduced the use of adjuvant chemotherapy without compromising recurrence risk or survival at two years.

"Detecting MRD has long been akin to looking for a needle in a haystack – we're searching for a small number of tumor-derived DNA molecules in a sea of normal molecules in a blood sample. If residual disease is detected, the patient journey can be transformed to greatly improve the likelihood of clinical benefit, and ultimately, save lives," said Dan Edelstein, President and CEO of Haystack. "Haystack's mission is to deliver earlier, more precise detection of residual and recurrent tumors to personalize therapy and dramatically improve outcomes for patients with cancer."

Related Links:
Haystack Oncology


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.